Revolution in Cell Therapy: In Vivo Chimeric-Antigen-Receptor-T-Cell Therapy Breakthroughs and Promises for the...

Area of Science:

• Immunotherapy
• Cellular Therapy
• Gene Therapy

Background:

• Traditional chimeric antigen receptor (CAR)-T-cell therapy shows success in hematological tumors but faces challenges like complex preparation, high costs, and limited efficacy in solid tumors.
• Limitations include in vitro manipulation, reduced T-cell function, dosing difficulties, and poor outcomes in solid tumor treatment.

Purpose of the Study:

• To review the current research landscape of in vivo CAR-T-cell therapy.
• To highlight the advantages of in situ CAR gene delivery for various diseases.
• To explore future directions and innovative solutions for in vivo CAR-T-cell therapy.

Main Methods:

• Review of existing literature on in vivo CAR-T-cell therapy.
• Analysis of delivery systems for in situ T-cell reprogramming.
• Examination of therapeutic applications in hematological malignancies, solid tumors, autoimmune diseases, and infectious diseases.

Main Results:

• In vivo CAR-T-cell therapy directly delivers CAR genes to host T cells, enabling in situ reprogramming.
• This method bypasses complex in vitro procedures, offering timely, cost-effective, and persistent treatment.
• Current research focuses on optimizing delivery systems, safety, and overcoming the tumor microenvironment for broader applications.

Conclusions:

• In vivo CAR-T-cell therapy presents significant advantages over traditional methods, particularly for solid tumors.
• Continued research into efficient delivery, safety, and functional optimization is crucial for expanding treatment indications.
• Technological breakthroughs and industrialization hold promise for the future of in vivo CAR-T-cell therapy.